AI Drug Firm METiS Considering $200 Million Hong Kong IPO, Sources Say
This article is for subscribers only.
Artificial intelligence-driven drug firm METiS Pharmaceuticals is considering an initial public offering in Hong Kong to raise as much as $200 million, according to people familiar with the matter.
The drug delivery and discovery company is working with advisers to arrange an IPO, potentially before the end of this year, the people said, asking not to be identified because the discussions aren’t public.